Practical modifications of the continual reassessment method for phase I cancer clinical trials.

@article{Faries1994PracticalMO,
  title={Practical modifications of the continual reassessment method for phase I cancer clinical trials.},
  author={Douglas E. Faries},
  journal={Journal of biopharmaceutical statistics},
  year={1994},
  volume={4 2},
  pages={147-64}
}
The continual reassessment method (1) (CRM) for phase I cancer trials provides improved estimation of the maximum tolerated dose (MTD), and fewer patients receive ineffective dose levels compared to the traditionally used design. However, the CRM has not gained acceptance in practice owing to concerns with administering dose levels that are too toxic. In this article, several conservative modifications of the CRM are introduced. The result is a procedure that improves estimation of the MTD and… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 65 extracted citations

dfcomb: An R-package for phase I/II trials of drug combinations

Computer Methods and Programs in Biomedicine • 2016
View 7 Excerpts
Highly Influenced

Advancing Clinical Trials to Streamline Drug Development.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2015

Adaptive clinical trial designs in oncology.

Chinese clinical oncology • 2014
View 3 Excerpts

Similar Papers

Loading similar papers…